96 Tests
GenScript cPass SARS-COV-2 Neutralization Antibody Detection Kit
£720.00
The GenScript cPassTM SARS-CoV-2 Neutralization Antibody Detection Kit is the first-in-the-world “rapid smart test kit”, with the capability of measuring functional neutralizing antibodies (Nabs) within an hour in most research or clinical labs. It is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating a prior infection.
Authorised distributor of 
Key Benefits
The GenScript cPassTM SARS-CoV-2 Neutralization Antibody Detection Kit is faster, easier, more scalable and automatable alternative to the traditional neutralizing antibody tests, such as virus neutralization test (VNT), pseudo-virus neutralization test (pVNT) and plaque reduction neutralization test (PRNT). These tests require the use of live virus, cells, highly skilled operators, and complex safety laboratory procedures (biosafety level 3) that are generally less sensitive and require several days to obtain results. In contrast, the cPass™ Neutralization Antibody Detection Kit can be rapidly conducted within an hour in most labs, and is also amenable to high throughput and fully automated testing.
Another key advantage of the cPass™ technology is that it is a highly specific and sensitive and in the same time isotype- and species-independent. Current antibody tests on the market are typically isotype-specific for just IgM or IgG, species specific for human antibodies only and cannot distinguish NAbs from other binding antibodies which do not possess neutralizing function.
Research Applications
This kit would be instrumental in vaccine and therapeutic development as it is suitable for all antibody isotypes and can be used to determine neutralizing antibodies in animal models without modification. The kit will also help in current COVID-19 investigations of sero-prevalence, assessment of herd immunity, longevity of protective immunity, efficacy of different vaccine candidates as well as tracking infection in animals. The cPass™ Neutralization Antibody Test is for research use only. Not for diagnostic use.
Publications showing value of the cPass Technology over gold standard serological tests
What is the cPass™ Technology?
The cPass™ technology allows for the rapid detection of total neutralizing antibodies (NAbs) in a sample by mimicking the interaction between the virus and the host cell. In order for a virus to infect a host cell, a viral receptor binding protein (RBD) first needs to interact with the host cell’s membrane receptor protein (ACE2).
The virus-host interaction and subsequent viral infection of the host cell leads to the activation of an individual’s immune response which generates a population of antibodies against the virus. Some of these antibodies can bind to the virus, but not necessarily block viral infection. Other antibodies can bind to the RBD in a way that blocks the interaction with the ACE2 receptor. The cPass™ technology helps to distinguish whether a sample contains NAbs that may specifically block the interaction and therefore the viral entry into the host cell.
Learn about COVID-19 and the importance of serology investigation in viral disease outbreak.
Dr. Linfa Wang, PhD, FTSE, is the director of the Program in Emerging Infectious Diseases at Duke-NUS Medical School in Singapore. His team at Duke-NUS, worked together with Diagnostics Development Hub and GenScript co-developed cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit.
Format: ELISA
Test/Kit: 96 Wells/Plate
Sample Type: Serum or Plasma
Protocol Time: 1 Hour
Relative Sensitivity: 93.80%
Relative Specificity: 99.40%
Materials Provided
• Capture Plate – 1 plate
• Positive Control – 1 vial (0.05 mL)
• Negative Control – 1 vial (0.05 mL)
• HRP conjugated RBD – 1 vial (0.02 mL)
• HRP Dilution Buffer – 1 bottle (10 mL)
• Sample Dilution Buffer – 1 bottle (30 mL)
• 20x Wash Solution – 1 bottle (40 mL)
• TMB Solution – 1 bottle (12 mL)
• Stop Solution – 1 bottle (6 mL)
• Plate Sealer – 2 pieces
Capture Plate: Pre-coated 96 well microplates ( 8 wells x 12 strips); 12 strips configured in plate sealed in a foil pouch with a desiccant.
Storage: The unopened kit is stable for at least 6 months from the date of manufacture if stored at 2 to 8°C, and the opened kit is stable for up to 1 month from the date of opening at 2 to 8°C.
How does the cPass SARS-CoV-2 Neutralization Antibody Test work?
Figure 1. Principle of the GenScript SARS-CoV-2 sVNT cPassTM test. Anti-SARS-CoV-2 neutralizing antibodies can block HRP-conjugated RBD protein binding (RBD-HRP) to the hACE2 protein pre-coated on capture plate.
Sample containing mixed COVID-19 antibodies (Neutralizing and Non-Neutralizing):
• Start by mixing the patient sample with the purified RBD-HRP complex mixture and incubate the mixture for 30 mins.
• Add the mixture into the sVNT kit plate which contains ACE2 receptors coated at the bottom of the wells.
• Figure 1 shows that three of the RBD-HRP complexes that are bound to the neutralizing antibodies (red) can’t bind to ACE2 Receptor except for one molecule only bound to non-neutralizing antibody (blue).
• Washing the plate will remove the unbound molecules and a light-yellow colour will form by adding TMB.
Sample with only non-neutralizing COVID-19 antibodies:
• Figure 1 shows that all four RBD-HRP are capable of binding to ACE2 receptors and will remain bound after the plate is washed. The addition of TMB will indicate a darker yellow colour.
Note: Horseradish Peroxidase (HRP) is a signal generating molecule for TMB. The intensity of the yellow colour increases with the quantity of HRP.
Read here for more information.
GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit – IFU
GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit – SDS
GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit – Certificate of Analysis
GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit – Disclaimer
Publications showing value of the cPass Technology over gold standard serological tests